Close Menu
The Startup StoryThe Startup Story
  • Business
  • Lifestyle
  • National
  • Education
  • Health
  • Technology
  • World

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

IBMA Organises First-Ever Indian Lead Battery Conference 2026 in Goa

November 20, 2026

Why Creator-Gear is a B2B Business now: agencies, schools, and production houses?

November 20, 2026

Prateek Group Brings The New Era of Luxury Real Estate

November 20, 2026
Facebook X (Twitter) Instagram
Trending
  • IBMA Organises First-Ever Indian Lead Battery Conference 2026 in Goa
  • Why Creator-Gear is a B2B Business now: agencies, schools, and production houses?
  • Prateek Group Brings The New Era of Luxury Real Estate
  • Top Bathroom Tile Brands in India: Wall, Floor and Anti-Skid Options Compared
  • Parul University moves to 401-500 band in Times Higher Education (THE) Interdisciplinary Science Rankings 2027
  • COLORFUL India Strengthens After-Sales Support Through Association with Kaizen Infoserve
  • ORGATEC India 2026 Outlines a Roadmap for Growth Amid a 15% Rise in Commercial Real Estate Investments
  • From Needle and Thread to Virar’s Spotlight: DhaagaDhari’s Handmade Brand Wins Hearts at Virar Flea Market
The Startup StoryThe Startup Story
  • Business
  • Lifestyle
  • National
  • Education
  • Health
  • Technology
  • World
The Startup StoryThe Startup Story
Home»Lifestyle»Blood Cancer in 2026: Why Treatment Decisions Are More Personal Than Ever
Lifestyle

Blood Cancer in 2026: Why Treatment Decisions Are More Personal Than Ever

Arjun SinghBy Arjun SinghSeptember 28, 2026No Comments
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

New Delhi [India], September 28: A diagnosis of blood cancer no longer arrives with a single, standard answer. The past decade has quietly rewritten what treatment looks like for many patients — from the person who lives with chronic leukaemia for many years without needing immediate treatment, to the lymphoma patient whose own immune cells can be re-engineered in a laboratory to fight their disease. For families weighing treatment options in India, understanding how much has changed is often the first step towards making an informed decision.

Not All Leukaemias Are Emergencies

The phrase “you have leukaemia” tends to trigger a very specific kind of panic: images of immediate hospitalisation, drips, hair loss and weeks of intensive treatment. For some blood cancers, that picture is accurate. For others, it is not.

Chronic Lymphocytic Leukaemia (CLL) sits firmly in the second category. It develops when a type of infection-fighting white blood cell — the lymphocyte — begins to accumulate slowly in the blood, bone marrow and lymph nodes. Progression is measured in years, sometimes decades, and many people are diagnosed only because a routine blood test shows an unusually high white cell count. A significant proportion of patients feel entirely well at the point of diagnosis.

For low-risk patients, the standard international approach may be active surveillance — regular blood counts and clinical review, but no immediate treatment. This can feel deeply counterintuitive. Research has shown that starting treatment early in patients without symptoms does not necessarily improve outcomes, while exposing them to treatment-related side effects. In this specific disease, watching closely can be an important part of treatment.

When Treatment Is Needed, It Looks Different

When CLL does progress — signalled by falling blood counts, rapidly enlarging lymph nodes, drenching night sweats or repeated infections — the therapy available today bears little resemblance to what patients received even ten years ago.

Targeted oral medicines now form an important part of treatment for many people. BTK inhibitors and BCL-2 inhibitors work by blocking specific molecular pathways that leukaemia cells depend on to survive. Many patients can take daily oral medicines rather than undergoing repeated cycles of intravenous chemotherapy, and durable remissions are increasingly possible.

Perhaps more importantly, patients with high-risk genetic features — historically the group with the worst outcomes — are among those benefiting from this shift. Genetic testing has therefore become an important part of treatment planning because it can help determine which treatment approach is most appropriate.

At the Other End of the Spectrum

Aggressive lymphomas such as Large B-cell Lymphoma allow no such patience. These are fast-growing cancers where treatment often needs to begin quickly, and standard first-line combination chemotherapy and antibody therapy can achieve remission or cure in a significant number of patients.

The harder question is what to offer those whose disease returns or does not respond adequately to initial treatment.

CAR-T cell therapy has, over the past several years, become an important treatment option for selected patients with certain relapsed or refractory blood cancers. The approach involves collecting a patient’s own T cells, genetically modifying them in a specialised laboratory to recognise cancer cells, and then infusing the cells back into the patient.

For some patients who have exhausted other treatment options, CAR-T therapy can produce significant and durable responses. However, it is a highly specialised treatment that requires careful patient selection, appropriate infrastructure and multidisciplinary expertise. The treatment journey also involves several stages, from cell collection and manufacturing to infusion and close monitoring afterwards.

What This Means for Indian Patients

The takeaway is not that blood cancer has become easy to treat — it has not. It is that the range of treatment options has widened substantially, and treatment decisions now depend on details that used to be less visible: the specific genetic and molecular characteristics of the cancer, the patient’s overall condition, previous treatments and the suitability of different therapeutic approaches.

For patients and families, three questions are worth asking of any treatment centre.

First, is molecular and genetic testing done routinely, and is it actively used to guide the treatment plan?

Second, is there a genuine multidisciplinary team — haematologists, transplant physicians, pathologists and cell therapy specialists — working together, or is care fragmented across referrals?

Third, is long-term follow-up built into the plan, or does the relationship end once the initial treatment phase is complete?

These questions matter far more today than they did a decade ago, because so much of what determines outcomes now happens beyond the infusion chair — in the genetic testing laboratory, the multidisciplinary meeting room and the follow-up clinics that monitor patients over time.

To learn more about modern care options, explore the educational resources in our Information Centre:

  • https://sunactcancer.com/chronic-lymphocytic-leukemia/
  • https://sunactcancer.com/ready-made-cell-therapy-a-new-hope-for-lymphoma-treatment/
lifestyle
Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
Arjun Singh
  • Website

Related Posts

From Needle and Thread to Virar’s Spotlight: DhaagaDhari’s Handmade Brand Wins Hearts at Virar Flea Market

November 20, 2026

Meeta Kotadia brings international recognition to India, winning the 2nd Runner-Up title along with two prestigious special awards at the global beauty pageant.

November 20, 2026

Invisalign by Dr. Swetha Reddy in Hyderabad Champions a “Diagnosis First” Approach as Gen Z Embraces Invisible Teeth Straightening

November 20, 2026

Comments are closed.

Top Posts

Parul University moves to 401-500 band in Times Higher Education (THE) Interdisciplinary Science Rankings 2027

November 20, 2026

Can we guess, how much she is happy?

February 22, 2020

When sunrise and the day begins.

February 22, 2020

Make your own inhouse library and learn

February 22, 2020
Don't Miss
Technology

IBMA Organises First-Ever Indian Lead Battery Conference 2026 in Goa

By Arjun SinghNovember 20, 2026

Panaji (Goa) [India], November 20: The Indian Battery Manufacturers Association (IBMA) successfully organised the first-ever…

Why Creator-Gear is a B2B Business now: agencies, schools, and production houses?

November 20, 2026

Prateek Group Brings The New Era of Luxury Real Estate

November 20, 2026

Top Bathroom Tile Brands in India: Wall, Floor and Anti-Skid Options Compared

November 20, 2026
Most Popular

Parul University moves to 401-500 band in Times Higher Education (THE) Interdisciplinary Science Rankings 2027

November 20, 2026

Can we guess, how much she is happy?

February 22, 2020

When sunrise and the day begins.

February 22, 2020
Categories
  • Business
  • Business News
  • Education
  • Entertainment
  • Finance
  • Health
  • Lifestyle
  • National
  • Press Release
  • Sports
  • Technology
  • Uncategorized
  • World
Our Picks

IBMA Organises First-Ever Indian Lead Battery Conference 2026 in Goa

November 20, 2026

Why Creator-Gear is a B2B Business now: agencies, schools, and production houses?

November 20, 2026

Prateek Group Brings The New Era of Luxury Real Estate

November 20, 2026

Type above and press Enter to search. Press Esc to cancel.